[Treatment of inflammatory diseases of the brain with kanamycin].
On the basis of clinical trials with 20 patients suffering from acute inflammatory diseases of the brain recommendations for determination of indications for rational use of kanamycin were formulated. Kanamycin proved to be effective in treatment of severe forms of neuroinfections caused by gramnegative bacteria, as well as mixed and resistant staphylococcal infections. With the account of the clinical state the use of the drug should be preceded by bacteriological tests with qualitative and quantitative determination of sensitivity of the isolates to the antibiotics.
D000328:Adult; D001100:Arachnoiditis / Q000188:drug therapy; D001927:Brain Diseases / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use*; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D008590:Meningoencephalitis / Q000188:drug therapy; D008875:Middle Aged; D009461:Neurologic Manifestations; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013492:Suppuration / Q000188:drug therapy; D014390:Tuberculosis, Meningeal / Q000188:drug therapy
D007612:Kanamycin
K lecheniiu vospalitel'nykh zabolevaniĭ golovnogo mozga kanamitsinom